If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
==== Benign soft tissue neoplasms ==== Peripheral nerve sheath tumours: These most commonly are traumatic neuromas, a reactive response to trauma, neurilemmoma and neurofibroma which are large growing painless tumours usually found on the tongue. Neurofibroma may occur as a benign solitary lesion but can present as multiple lesions associated with (Von Reckllinghausen's Disease) neurofibromatosis. They can be preceded by café au lait pigmentation spots on the skin, and as they grow can become very disfiguring. Malignant change can occur in neurofibromatosis but very rarely in single lesion presentation. Mucosal neuromas can be associated with other conditions such as multiple endocrine neoplasia (MEN) syndrome and may precede thyroid cancer. Lipoma and fibrolipoma: These are tumours of adipose tissue, or fat, giving them a yellow appearance which varies according to fat content. They are usually soft, mobile, slow growing painless and occur mostly in middle age or the elderly. Granular cell tumour: These are also tumours arising from neural cells, though it was incorrectly thought to arise from muscle cells and therefore previously called granular cell myoblastoma. It also is slow growing large painless and occurs mostly in the tongue. Congenital epulis: These are also known as congenital granular cell tumours (but not related to granular cell tumours), and occur mostly on the upper gum, the maxillary alveolar ridge, of newborns, predominantly females. Rarely, they occur elsewhere, usually the tongue. They are usually self-resolving.
== History == In 1962, Stanozolol was brought to market in the US by Winthrop under the tradename "Winstrol" and in Europe by Winthrop's partner, Bayer, under the name "Stromba". Also in 1962, the Kefauver Harris Amendment was passed, amending the Federal Food, Drug, and Cosmetic Act to require drug manufacturers to provide proof of the effectiveness of their drugs before approval. The FDA implemented its Drug Efficacy Study Implementation (DESI) program to study and regulate drugs, including stanozolol, that had been introduced prior to the amendment. The DESI program was intended to classify all pre-1962 drugs that were already on the market as effective, ineffective, or needing further study. The FDA enlisted the National Research Council of the National Academy of Sciences to evaluate publications on relevant drugs under the DESI program. In June 1970 the FDA announced its conclusions on the effectiveness of certain AAS, including stanozolol, based on the NAS/NRC reports made under DESI. The drugs were classified as probably effective as adjunctive therapy in the treatment of senile and postmenopausal osteoporosis but only as an adjunct, and in pituitary dwarfism (with a specific caveat for dwarfism, "until growth hormone is more available"), and as lacking substantial evidence of effectiveness for several other indications.
28 February to 8 May The U.S. 101st Airborne Division and ARVN 1st Division launched Operation Massachusetts Striker to keep pressure on the PAVN in the southern A Shau Valley. The operation results in 223 PAVN killed and two captured while U.S. losses were 59 killed.
Functional metagenomics has enabled the discovery of several new antimicrobial resistance mechanisms and their related genes, one such example is the recently discovered tetracycline resistance mechanism by tetracycline destructases. It is important to incorporate not only the antimicrobial resistance gene sequence and mechanism but also the genomic context, host bacterial species and geographic location (metagenome).
=== Pharmacokinetics === The time to peak concentrations following a dose is 2 to 4 hours. The typical antidepressant therapeutic range of trimipramine concentrations is 150 to 300 ng/mL. The terminal half-life of trimipramine has been variously reported to be as little as 8 hours (in plasma) and as long as 24 hours. In any case, the terminal half-life of trimipramine is described as shorter than that of other TCAs, which makes it ideal for use in the treatment of insomnia. Trimipramine is a racemic compound with two enantiomers.[1] CYP2C19 is responsible for the demethylation of (D)- and (L)-trimipramine to (D)- (L)-desmethyltrimipramine, respectively, and CYP2D6 is responsible for the 2-hydroxylation of (D)- and (L)-desmethyltrimipramine to (D)- and (L)-2-hydroxydesmethyltrimipramine, respectively. CYP2D6 also metabolizes (L)-trimipramine into (L)-2-hydroxytrimipramine.
Sources: en.wikipedia.org
=== Anti-CD47 therapy === Many tumor cells overexpress CD47 to escape immunosurveilance of host immune system. CD47 binds to its receptor signal-regulatory protein alpha (SIRPα) and downregulate phagocytosis of tumor cell. Therefore, anti-CD47 therapy aims to restore clearance of tumor cells. Additionally, growing evidence supports the employment of tumor antigen-specific T cell response in response to anti-CD47 therapy. A number of therapeutics are being developed, including anti-CD47 antibodies, engineered decoy receptors, anti-SIRPα antibodies and bispecific agents. As of 2017, wide range of solid and hematologic malignancies were being clinically tested.
Technology While Minds would likely have different capabilities, especially seeing their widely differing ages (and thus technological sophistication), this is not a theme of the books. It might be speculated that the older Minds are upgraded to keep in step with the advances in technology, thus making this point moot. It is also noted in Matter that every Culture Mind writes its own OS, thus continually improving itself and, as a side benefit, becoming much less vulnerable to outside takeover by electronic means and viruses, as every Mind's processing functions work differently. The high computing power of the Mind is apparently enabled by thought processes (and electronics) being constantly in hyperspace (thus circumventing the light speed limit in computation). Minds do have back-up capabilities functioning with light-speed if the hyperspace capabilities fail – however, this reduces their computational powers by several orders of magnitude (though they remain sentient). The storage capability of a GSV Mind is described in Consider Phlebas as 1030 bytes (1 million yottabytes). The Culture is a society undergoing slow (by present-day Earth standards) but constant technological change, so the stated capacity of Minds is open to change. In the last 3,000 years, the capacity of Minds has increased considerably. By the time of the events of the novel Excession in the mid 19th century, Minds from the first millennium BCE are referred to jocularly as minds, with a small 'm'.
== Properties == PAW contains reactive oxygen and nitrogen species, with a pH lower than untreated water along with higher electrical conductivity. PAW has disinfective properties: the oxidative stress that it causes on the cell membranes of the bacterial cells results in disruption of the cell membrane, followed by further damage that leads to cell death.
The 2024 edition of the FAO report The State of Food and Agriculture 2024 adopts an agrifood systems typology with six categories – protracted crisis, traditional, expanding, diversifying, formalizing and industrial – to reveal that different systems face unique challenges and require targeted interventions. The typology uses a set of four variables, comprising agricultural value added per worker, number of supermarkets per capita, diet diversity, and urbanization. It is based on the food systems typology developed by Marshall et al. (2021) with the aim to offer a distinct classification of countries based on various aspects of their national agrifood systems, serving as a valuable addition to context-specific studies. The FAO typology adds the category for protracted crises to address the major disruptions caused by prolonged conflicts and vulnerabilities in agrifood systems, following the designation made in the "Global Report on Food Crises."
Alongside its priority for a reduction of global economic imbalances, France also identified support for Ukraine, protection of children, the fight against organised crime and illegal flows, and reform of global governance as major themes of the summit. G7 leaders adopted joint statements on mutually beneficial international partnerships, the Bundibugyo Ebola outbreak, cancer, geopolitical issues, migrant smuggling, drug trafficking, online safety for minors, balanced growth and critical mineral supply chains. In a statement on global imbalances, leaders called for stronger International Monetary Fund surveillance of external imbalances and asked the IMF and the OECD to monitor how domestic policy in major economies contributes to those imbalances. Egypt, Kenya and South Korea also supported the statement. The discussions included concerns over Chinese export practices, industrial overcapacity, subsidies and weak domestic consumption. The French foreign ministry described the 2026 summit as the first G7 leaders' summit to make cancer a priority, with objectives including support for research, data sharing and efforts to reduce cancer mortality. The health-related statements called for cooperation on cancer and announced more than $1 billion in funding for the response to the Bundibugyo Ebola outbreak, in line with United Nations efforts.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.